Last10K.com

Aeolus Pharmaceuticals, Inc. (AOLS) SEC Filing 8-K Material Event for the period ending Tuesday, February 23, 2016

Aeolus Pharmaceuticals, Inc.

CIK: 1261734 Ticker: AOLS

View differences made from one to another to evaluate Aeolus Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aeolus Pharmaceuticals, Inc..

Continue

Assess how Aeolus Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aeolus Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2016 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools
Ticker: AOLS
CIK: 1261734
Form Type: 8-K Corporate News
Accession Number: 0001102624-16-002174
Submitted to the SEC: Tue Feb 23 2016 12:39:05 PM EST
Accepted by the SEC: Tue Feb 23 2016
Period: Tuesday, February 23, 2016
Industry: Pharmaceutical Preparations
Events:
  1. Other Events

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/aols/0001102624-16-002174.htm